BR112017013012A2 - compostos de indenil, composições farmacêuticas e usos médicos destes - Google Patents

compostos de indenil, composições farmacêuticas e usos médicos destes

Info

Publication number
BR112017013012A2
BR112017013012A2 BR112017013012-2A BR112017013012A BR112017013012A2 BR 112017013012 A2 BR112017013012 A2 BR 112017013012A2 BR 112017013012 A BR112017013012 A BR 112017013012A BR 112017013012 A2 BR112017013012 A2 BR 112017013012A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
medical uses
indenyl compounds
indenyl
compounds
Prior art date
Application number
BR112017013012-2A
Other languages
English (en)
Inventor
A. Piazza Gary
Chen Xi
B. KEETON Adam
R. Boyd Michael
Original Assignee
Adt Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adt Pharmaceuticals, Inc filed Critical Adt Pharmaceuticals, Inc
Publication of BR112017013012A2 publication Critical patent/BR112017013012A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
BR112017013012-2A 2014-12-16 2015-12-16 compostos de indenil, composições farmacêuticas e usos médicos destes BR112017013012A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/571,647 2014-12-16
US14/571,647 US9862698B2 (en) 2014-12-16 2014-12-16 Indenyl compounds, pharmaceutical compositions, and medical uses thereof
PCT/US2015/066146 WO2016100542A1 (en) 2014-12-16 2015-12-16 Indenyl compounds, pharmaceutical compositions, and medical uses thereof

Publications (1)

Publication Number Publication Date
BR112017013012A2 true BR112017013012A2 (pt) 2018-06-26

Family

ID=55085918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013012-2A BR112017013012A2 (pt) 2014-12-16 2015-12-16 compostos de indenil, composições farmacêuticas e usos médicos destes

Country Status (16)

Country Link
US (7) US9862698B2 (pt)
EP (2) EP4053105A1 (pt)
JP (3) JP6698089B2 (pt)
KR (1) KR20170135820A (pt)
CN (2) CN107531615B (pt)
AU (1) AU2015364696B2 (pt)
BR (1) BR112017013012A2 (pt)
CA (1) CA2970803A1 (pt)
CL (1) CL2017001539A1 (pt)
CO (1) CO2017007076A2 (pt)
IL (1) IL252897A0 (pt)
MX (2) MX2021012096A (pt)
PH (1) PH12017501130A1 (pt)
RU (1) RU2017125024A (pt)
SG (1) SG11201704934YA (pt)
WO (1) WO2016100542A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862698B2 (en) * 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3056873A1 (en) 2017-03-17 2018-09-20 University Of South Alabama Derivatives of sulindac can protect normal cells against oxidative damage
EP3676242B1 (en) 2017-08-31 2024-03-06 Musc Foundation for Research Development Indene derivatives and uses thereof
US11186596B2 (en) 2018-04-26 2021-11-30 Adt Pharmaceuticals, Llc Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses
CN113289020B (zh) * 2021-05-17 2023-04-18 福州大学 蛋白质二硫键异构酶小分子抑制剂及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325358A (en) * 1962-06-06 1967-06-13 Merck & Co Inc Method of treating inflammation
NL7005270A (pt) 1969-04-29 1970-11-02
US3888902A (en) 1972-10-30 1975-06-10 Merck & Co Inc Cyano-indenyl acetic acids
US3642785A (en) 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
NL7200058A (pt) 1971-01-21 1972-07-25
FI750366A (pt) * 1974-02-28 1975-08-29 Merck & Co Inc
ATE40561T1 (de) 1983-07-21 1989-02-15 Troponwerke Gmbh & Co Kg Antiphlogistika enthaltende thermoplastische kunststoffe.
US4656190A (en) 1983-11-14 1987-04-07 Merck & Co., Inc. Indene derivatives and their use as PAF-antagonists
US5093356A (en) 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
DE69202721T2 (de) 1991-03-08 1995-10-12 Fgn Inc Substituierte Indenylverbindungen.
US5401774A (en) 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
WO1996004266A2 (de) 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US6121321A (en) 1996-06-13 2000-09-19 Cell Pathways, Inc. Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
US5965619A (en) 1996-06-13 1999-10-12 Cell Pathways Inc. Method for treating patients having precancerous lesions with substituted indene derivatives
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
HUP9903620A3 (en) 1997-06-12 2001-03-28 Univ Arizona Tucson Pharmaceutical compositions containing substituted benzylidene indenyl formamides, acetamide and propionamide derivatives and use of these compounds
TR200001687T2 (tr) 1997-12-12 2000-10-23 Cell Pathways, Inc. Neopleasyo için N-benzil-3-indenilasetamid türevleri.
US6028116A (en) * 1998-04-03 2000-02-22 Cell Pathways, Inc. Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
US6025394A (en) * 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
MXPA02006312A (es) 1999-12-23 2004-06-21 Nitromed Inc Inhibidores de ciclooxigenasa-2 nitrosilatados y nitrosados, composiciones y metodos para utilizarse.
EP1157027B1 (en) 1999-12-28 2007-09-19 Basell Polyolefine GmbH Heterocyclic metallocene compounds and use thereof in catalyst systems for producing olefin polymers
JP2004510762A (ja) 2000-10-02 2004-04-08 メルク　エンド　カムパニー　インコーポレーテッド プレニル−蛋白質トランスフェラーゼの阻害剤
US20030176316A1 (en) * 2001-08-24 2003-09-18 Whitehead Clark M. Methods for treatment of rheumatoid arthritis
DE10163426A1 (de) 2001-12-21 2003-07-03 Max Planck Gesellschaft Pharmakologisch wirksame Inden-Derivate
US20030194750A1 (en) 2002-04-05 2003-10-16 Han Li Methods for treatment of diseases where GSK 3-beta is desired, and methods to identify compounds usefule for that
US6538029B1 (en) 2002-05-29 2003-03-25 Cell Pathways Methods for treatment of renal cell carcinoma
EP1539679A4 (en) 2002-06-28 2007-07-04 Nitromed Inc OXIM- AND / OR HYDRAZO-CONTAINING, NITROSED AND / OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND USE METHODS
EP1744747A4 (en) 2004-04-26 2009-12-02 Univ Vanderbilt INDIC ACID AND INDULECTIC ACID DERIVATIVES AS THERAPEUTIC ACTIVITIES WITH REDUCED GASTROINTESTINAL TOXICITY
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007054257A2 (en) 2005-11-08 2007-05-18 Laboratorios Del Dr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EA016323B1 (ru) 2006-01-04 2012-04-30 Саутерн Рисерч Инститьют Производные сулиндака, их применение и получение
JP5759672B2 (ja) 2006-07-09 2015-08-05 テックフィールズ バイオケム カンパニー リミテッド アスピリンの正荷電水溶性プロドラッグ
WO2008044095A1 (en) 2006-10-11 2008-04-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
WO2008012603A1 (en) 2006-07-26 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
AU2016219617B2 (en) 2006-07-09 2018-05-17 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
AU2013206215C9 (en) 2006-07-09 2018-03-08 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
AU2013231152B2 (en) 2006-07-18 2016-06-09 Techfields Biochem Co. Ltd Positively charged water-soluble pro-drugs of ibuprofen
DK2041068T3 (en) 2006-07-18 2017-02-27 Techfields Biochem Co Ltd POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED
PL2046727T3 (pl) 2006-07-25 2014-08-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę
CN101500984A (zh) 2006-07-27 2009-08-05 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性酮洛芬及相关化合物的前药
EA018724B1 (ru) 2006-08-07 2013-10-30 Айронвуд Фармасьютикалз, Инк. Соединения индола
PL2049482T3 (pl) 2006-08-08 2016-04-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę
CA2660814C (en) 2006-08-15 2017-07-18 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
AU2013206218B2 (en) 2006-08-15 2016-06-30 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
PL2084132T3 (pl) 2006-09-03 2019-03-29 Techfields Biochem Co. Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry
EP2061749B1 (en) 2006-09-03 2018-02-21 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
AU2014201024B2 (en) 2006-09-03 2016-05-05 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
AU2007354632B2 (en) 2007-06-04 2014-06-26 Techfields Inc Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses
EA201201031A1 (ru) 2010-01-25 2013-02-28 Энанта Фармасьютиклз, Инк. Ингибиторы вируса гепатита с
BR112013024525A2 (pt) 2011-04-01 2017-04-18 Southern Res Inst compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica
EP2897621A4 (en) 2012-09-21 2016-08-10 Basil Rigas COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES, PAIN AND FEVER, SKIN DISEASES, CANCER AND PRECULTURAL INJURIES
CA2908383A1 (en) 2013-04-09 2014-10-16 Materia, Inc. Preparation of surfactants via cross-metathesis
WO2015126462A1 (en) 2014-02-19 2015-08-27 Materia, Inc. Preparation of surfactants via cross-metathesis
US20160168108A1 (en) * 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US20170342021A1 (en) 2014-12-16 2017-11-30 Adt Pharmaceuticals, Inc. Ras-inhibiting indenyl acetamide compounds, compositions, and uses
US9862698B2 (en) * 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
WO2017106520A1 (en) 2015-12-16 2017-06-22 Adt Pharmaceuticals, Inc. Compounds, compositions and methods of treating cancer
US11186596B2 (en) 2018-04-26 2021-11-30 Adt Pharmaceuticals, Llc Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses

Also Published As

Publication number Publication date
US20160168113A1 (en) 2016-06-16
AU2015364696A1 (en) 2017-07-06
EP4053105A1 (en) 2022-09-07
EP3233794B1 (en) 2023-02-01
JP2018505145A (ja) 2018-02-22
CO2017007076A2 (es) 2018-01-05
JP2021185193A (ja) 2021-12-09
KR20170135820A (ko) 2017-12-08
CA2970803A1 (en) 2016-06-23
US20200048217A1 (en) 2020-02-13
IL252897A0 (en) 2017-08-31
US10526307B2 (en) 2020-01-07
PH12017501130A1 (en) 2017-11-27
CL2017001539A1 (es) 2018-03-23
US20180208573A1 (en) 2018-07-26
US20200223815A1 (en) 2020-07-16
US10975054B2 (en) 2021-04-13
RU2017125024A (ru) 2019-01-17
US11130744B2 (en) 2021-09-28
US20200223816A1 (en) 2020-07-16
US9862698B2 (en) 2018-01-09
US11407727B2 (en) 2022-08-09
JP6698089B2 (ja) 2020-05-27
CN107531615A (zh) 2018-01-02
MX2017007840A (es) 2018-03-01
US20220315553A1 (en) 2022-10-06
CN112047909A (zh) 2020-12-08
JP2020079307A (ja) 2020-05-28
MX2021012096A (es) 2022-10-25
SG11201704934YA (en) 2017-07-28
AU2015364696B2 (en) 2020-10-15
EP3233794A1 (en) 2017-10-25
WO2016100542A1 (en) 2016-06-23
CN107531615B (zh) 2020-09-04
US10981886B2 (en) 2021-04-20
US20200031795A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
BR112016023628A2 (pt) composições farmacêuticas.
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
MA50541A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3199161T3 (da) Farmaceutisk præparat
DK3634377T3 (da) Farmaceutisk formulering
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
DK3157506T3 (da) Smagsmaskeret oral, farmaceutisk sammensætning
DK3280447T3 (da) Farmaceutiske formuleringer
DK3601277T3 (da) Farmaceutisk formulering
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
DK2915526T3 (da) Farmaceutiske sammensætninger, der omfatter anagrelid

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ADT PHARMACEUTICALS, LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]